QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AORT

QT43Artivion, Inc.
NYSE·Healthcare·Medical - Devices·USA
Latest market price
21.19
-0.01-0.05%
OverviewShort InterestFilings
AORTQT43Artivion, Inc.·NYSE
OverviewShort InterestFilings
21.19-0.05%
TA
Loading chart...
Screen all →
ABT-0.10%$88.41ISRG+1.14%$406.78SYK+2.21%$307.80MDT+1.54%$79.34BSX+0.76%$45.29EW+0.78%$87.36DXCM+1.74%$72.47RMD+1.26%$188.63
Snapshot
Index-P/E87.18EPS (ttm)0.24
Insider Own6.75%
Shs Outstand48.54M
Perf Week2.86%
Market Cap1.03BForward P/E49.57EPS next Y0.43Insider Trans-0.18%Shs Float-Perf Month-6.78%
Enterprise Value1.23BPEG0.18EPS next Q-Inst Own-Short Float-Perf Quarter-41.99%
Income11.83MP/S2.24EPS this Y-48.44%Inst Trans-Short Ratio-Perf Half Y-53.84%
Sales458.70MP/B2.26EPS next Y245.45%ROA1.32%Short Interest-Perf YTD-53.54%
Book/sh9.27P/C18.12EPS next 5Y88.73%ROE2.66%52W High48.25 -56.08%Perf Year-28.82%
Cash/sh1.15P/FCF80.21EPS past 3/5Y-ROIC3.00%52W Low19.16 10.59%Perf 3Y-
Dividend Est.-EV/EBITDA18.93Sales past 3/5Y11.99% 11.75%Gross Margin62.94%Volatility3.32% 3.12%Perf 5Y-
Dividend TTM-EV/Sales2.68EPS Y/Y TTM-Oper. Margin7.76%ATR (14)1.22Perf 10Y-
Dividend Ex-DateDec 09, 2015Quick Ratio2.22Sales Y/Y TTM17.74%Profit Margin2.55%RSI (14)37.12Recom2.00
Dividend Gr. 3/5Y33.89% -Current Ratio3.28EPS Q/Q-SMA20-0.59%Beta0.72Target Price40.50
Payout0.00%Debt/Eq0.57Sales Q/Q17.17%SMA50-24.71%Rel Volume1.41Prev Close21.20
Employees1,600LT Debt/Eq0.64Earnings-SMA200-44.73%Avg Volume707.85KPrice21.19
IPO DateFeb 12, 1993Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA3.11Volume1,000,678Change-0.05%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-16-26ReiteratedCanaccord GenuityBuy$51 → $36
Jun-01-26ReiteratedStifel Nicolaus$55 → $45
Apr-10-26UpgradeLadenburg ThalmannNeutral → Buy
Mar-05-26ReiteratedStifel Nicolaus$55
Dec-17-25ReiteratedCanaccord GenuityBuy$51
Nov-07-25ReiteratedOppenheimerOutperform$30 → $50
Aug-13-25DowngradeLadenburg ThalmannBuy → Neutral
Aug-08-25ReiteratedNeedhamBuy$30 → $45
Oct-23-24ReiteratedJMP Securities$33
Aug-09-24ReiteratedOppenheimerOutperform$30
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue458441389
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A170171140
Gross Profit289270249
Selling, General and Administrative Excl. Other221213192
Research and Development333128
Other Operating Expense-10-10
Operating Income352739
Interest Expense242734
Unusual Expense
———
Non-Operating Income (Expense)-6-1512
Net Income Before Taxes1715-8
Income Taxes656
Consolidated Net Income1110-13
Net Income From Continuing Operations1110-13
Net Income1110-13
EPS (Recurring)0.250.22-0.32
EPS (Basic, Before Extraordinaries)0.250.22-0.32
EPS (Diluted)0.240.21-0.32
EBITDA656451
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio88.29217.19—
Price To Sales Ratio2.224.65—
Gross Margin63.1061.2264.01
Operating Margin7.646.1210.03
Net Margin2.402.27-3.34
Shares Outstanding484542
Market Capitalization1,0172,052—
Operating Lease Expense
———
Insider Trading Volume
$22.70$20.60$18.50$16.40$14.30● Close Price0.00M2.17M4.33M6.50M8.67MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Sale20.7044,001910,73960,259Jun 15 12:00 AM
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Option Exercise13.3988,0021,178,15690,259Jun 15 12:00 AM
Holloway Jean FSVP, General CounselMar 04 '26Sale38.008,962340,556185,095Mar 04 12:00 AM
Berry Lance AEVP, COO, CFO & TreasurerMar 03 '26Sale37.786,316238,591210,827Mar 04 12:00 AM
Horton AmyVP, Chief Accounting OfficerMar 03 '26Sale37.7890134,036139,088Mar 04 12:00 AM
Holloway Jean FSVP, General CounselMar 03 '26Sale37.783,843145,172194,057Mar 04 12:00 AM
Stanton Marshall S.SVP, Clinical & MD AffairMar 03 '26Sale37.782,14981,18060,097Mar 04 12:00 AM
Davis John EChief Commercial OfficerMar 03 '26Sale37.784,573172,748230,794Mar 04 12:00 AM
Mackin James PPresident & CEOMar 03 '26Sale37.7817,887675,692947,275Mar 04 12:00 AM
Horton AmyVP, Chief Accounting OfficerMar 02 '26Sale38.0264124,374132,514Mar 03 12:00 AM
Stanton Marshall S.SVP, Clinical & MD AffairMar 02 '26Sale38.021,51357,53240,408Mar 03 12:00 AM
Mackin James PPresident & CEOMar 02 '26Sale38.0214,911566,989848,214Mar 03 12:00 AM
Holloway Jean FSVP, General CounselMar 02 '26Sale38.022,18383,008170,105Mar 03 12:00 AM
Berry Lance AEVP, COO, CFO & TreasurerMar 02 '26Sale38.025,178196,893176,269Mar 03 12:00 AM
Davis John EChief Commercial OfficerMar 02 '26Sale38.022,784105,861206,522Mar 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR